Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible

Acute Myeloid Leukemia Clinical Trial

— PAZOPANIB-AML  

Official title:

Phase II Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01361334
• Other study ID #: UKM09_0018_PAZOPANIB_AML 2011
• Secondary ID: 2010-024526-37
• Status: Completed
• Phase: Phase 2
• Start date: June 2011
• Est. completion date: March 2016

Study information

• Verified date: May 2016
• Source: University Hospital Muenster
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Long term disease-free survival (DFS) of patients with acute myeloid leukemia (AML) is still poor. Recently, so-called "targeted therapy" for cancer has been introduced to the treatment of patients with AML. This phase II clinical trial will explore the efficacy, safety, and pharmacodynamics of the tyrosine kinase inhibitor pazopanib in patients with relapsed or refractory AML or patients with AML who are not eligible for intensive treatment. Biomarker studies will be included to study whether the targets are indeed inhibited and whether this leads to decreased BM angiogenesis. Toxicity assessments will be included, and the antileukemic effectiveness will be studied.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: March 2016
• Est. primary completion date: March 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects must provide written informed consent prior to performance of study-specific procedures or assessments which are not routinely performed for diagnosis or monitoring of acute myeloid leukemia (AML), and the subjects must be willing to comply with treatment and to follow up assessments and procedures

2. Histologically or cytologically confirmed diagnosis of AML relapsed after or refractory to at least one induction regimen, or patients with AML at initial diagnosis who are not eligible for allogeneic transplant or intensive induction chemotherapy, except for AML M3 (acute promyelocytic leukemia)

3. Age at least 18 years

4. Eastern Cooperative Oncology Group (ECOG) performance status of =3

5. Measurable disease burden (blasts in BM and/or PB, extramedullary blasts [chloroma])

6. Able to swallow and retain oral medication

7. A life expectancy of at least 4 weeks

8. Adequate contraception methods

9. Adequate organ function as defined in the study protocol

Exclusion Criteria:

1. Patients with a valid option for intensive chemotherapy and/or stem cell transplantation (Patients after allogeneic stem cell transplant must be off immunosuppressive agents for at least 2 weeks prior to study entry and Graft-versus host disease must have resolved to Grade =2)

2. History of cancer that according to the Investigator might confound the assessment of the endpoints of the study

3. Uncontrolled peptic ulcer disease or clinically significant gastrointestinal abnormalities which interfere with oral dosing or any unstable or serious concurrent condition (e.g., active uncontrolled infection)

4. Poorly controlled hypertension [defined as systolic blood pressure (SBP) of =140 mmHg or diastolic blood pressure (DBP) of =90 mmHg]. Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. BP must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP / DBP values from each BP assessment must be <140/90 mmHg in order for a subject to be eligible for the study

5. Prolongation of corrected QT interval (QTc) >480 milliseconds

6. History of any one of more of the following cardiovascular conditions within the past 6 months: cardiac angioplasty or stenting, myocardial infarction, unstable angina, symptomatic peripheral vascular disease, class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)

7. History of cerebrovascular infarction or bleeding, pulmonary embolism, or untreated deep venous thrombosis (DVT) within the past 6 months. Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulant agents for at least 6 weeks are eligible

8. Evidence of serious active bleeding or bleeding diathesis (except for bleeding or petechiae due to AML-related thrombocytopenia which will be treated using platelet transfusions). Also, patients with known endobronchial lesions and/or lesions infiltrating major pulmonary vessels will be excluded from the study due to excess risk of bleeding.

9. Prior major surgery or trauma within 28 days prior to first dose of study drug

10. Treatment with an investigational agent within 28 days or 5 half-lives, whichever is longer prior to the first dose of study drug (for bevacizumab 60 days).

11. Concurrent cytoreductive chemotherapy (hydroxyurea must be discontinued at least one day before start of study medication)

12. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to pazopanib

13. Patients with psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol

14. Pregnant or lactating and actively breastfeeding patients

15. Patients taking any of the following prohibited medication:

• clarithromycin, telithromycin, troleandomycin (antibiotics)
• ritonavir, indinavir, saquinavir, nelfinavir, amprenavir, lopinavir (HIV protease inhibitors)
• itraconazole, ketoconazole, voriconazole, fluconazole (antifungals)
• nefazodone (antidepressant)

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• Pazopanib
800 mg QD p.o.

Locations

Country	Name	City	State
Germany	Unviersity Hospital of Münster (UKM)	Münster

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital Muenster	Novartis

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cumulative response rate (CR, CRp, CRi, PR) within up to one year of pazopanib treatment		12 months
Primary	Reduction of BM microvessel density on day 28		28 days
Secondary	Safety and Tolerability (Rate of adverse events)	Rate of adverse events	12 months
Secondary	Cumulative incidence and degree of inhibition of target receptor phosphorylation (PDGFR, VEGFR, and c-KIT) and correlation with clinical response		12 months
Secondary	Reduction of BM microvessel density on day 14		14 days
Secondary	Relapse-free survival in relationship to historical control patients, Overall survival in relationship to historical control patients, Duration of response		12 months